Can I read The next generation: etravirine in the treatment of HIV-1 infection in adults refractory to other antiretrovirals on EtoBox?

The next generation: etravirine in the treatment of HIV-1 infection in adults refractory to other antiretrovirals by Liedtke, Michelle; Rathbun, is a scholarly article available to read on EtoBox.

What is The next generation: etravirine in the treatment of HIV-1 infection in adults refractory to other antiretrovirals about?

Etravirine is a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) that is approved for the treatment of adult human immunodeficiency virus (HIV)infected patients with documented or suspected resistance to first-generation NNRTIs. Etravirine has a flexible molecular structure that allows it to retain its activity against mutant HIV strains that exhibit resistance to first-generation agents. It is evident that 3 or more etravirine resistance-associated mutations are typically necessary before clinical resistance to etravirine. Safety and efficacy of etravirine are established in antiretroviral treatment-experienced patients in combination with antiretroviral regimens that contain darunavir/ritonavir. In phase III studies, cutaneous reactions occurred in 19% of treated patients and are the most commonly observed adverse event. The typical manifestation is the development of a maculopapular rash within the first few weeks of etravirine therapy. Resolution commonly occurs within 1-2 weeks on continued therapy. Rare cases of severe skin reactions (,0.1%) have been reported. Etravirine is hepatically metabolized by cytochrome P450 (CYP) 3A4, CYP2C9, and CYP2C19. Drug

Author

Liedtke, Michelle; Rathbun,

Publisher

Dove Press Ltd.; Dove Medical Press; Dove Medical Press Ltd; [Auckland N.Z.]: Dove Medical Press, c2009-[2018]; Informa UK Limited; Dove Medical Press Ltd. (ISSN 1179-1624)

Published

2010

Language

EN